Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04154631 · ClinicalTrials.gov registry record · NA
Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes
A NA study, sponsored by University of California, Berkeley.
- Completed
- Registry status
- NA
- Development phase
- 489
- Enrollment target
NCT04154631: Completed NA study, sponsored by University of California, Berkeley.
NCT04154631 is a NA study that has completed, run by University of California, Berkeley. The registered enrollment target is 489 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04154631, a NA study, has completed, sponsored by University of California, Berkeley.
- COMPLETED
- Registry status
- NA
- Development phase
- 489 participants
- Enrollment target
Study Summary
The sleep disturbance commonly experienced by individuals with a severe mental illness (SMI) reduces these individuals' capacity to function and contributes to key symptoms. This study will test the effects of a sleep treatment that has been adapted using theory, data and stakeholder inputs to improve the fit for SMI patients treated in community mental health centers (CMHCs), relative to the standard treatment. The investigators will also determine if the adapted and standard versions can improve sleep, improve functioning and reduce symptoms.
Primary Outcome
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance Scale. The 8-item short version scale assesses perceived sleep problems (e.g., sleep quality, perception of sleep difficulties) over a 7-day period. Items are rated on a 5-point scale ranging from 1 (not at all) to 5 (very much). Raw scores are summed to produce a single score, resulting in a range from 8 to 40. Raw scores are converted to t-scores using treatment manuals. T-scores range from 30.5 to 77.5. A T-sc
Interventions
- BEHAVIORAL Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
- BEHAVIORAL Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)
- OTHER Usual Care Delayed Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2020-01-08 |
| Est. Completion | 2023-12-19 |
| Phase | NA |
What the finished NCT04154631 record still lists
NCT04154631 is an interventional study that assigns participants to a tested intervention. The registered 489 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is the first listed.
NCT04154631 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04154631 about?
NCT04154631 is a clinical study titled "Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes". The sleep disturbance commonly experienced by individuals with a severe mental illness (SMI) reduces these individuals' capacity to function and contributes to key symptoms. This study will test the effects of a sleep treatment that has been adapted using theory, data and stakeholder inputs to impro...
What is the current status of trial NCT04154631?
This trial is currently completed. It is a NA study. The enrollment target is 489 participants. The study started on 2020-01-08. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT04154631?
The interventions under investigation include: Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) (BEHAVIORAL), Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) (BEHAVIORAL), Usual Care Delayed Treatment (OTHER).
Who is sponsoring clinical trial NCT04154631?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04154631's enrollment target sits among peer trials
489 215th of 2000 higher than 1,786 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI